Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab

Israel Medical Association Journal

Volumn 15, Issue 7, 2013, Pages 352-355

  Segal, Ori ^a,b   Ferencz, Joseph R ^a,b   Cohen, Perri ^a,b   Nemet, Arie Y ^a,b   Nesher, Ronit ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Age related macular degeneration (AMD); Anti vascular endothelial growth factor (VEGF); Avastin; Bevacizumab; Glaucoma; Intraocular pressure (IOP); Intravitreal injection

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB;

AGED; ARTICLE; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; TRABECULECTOMY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; ISRAEL; MACULAR DEGENERATION; MALE; MEDICAL RECORDS, PROBLEM-ORIENTED; MIDDLE AGED; OCULAR HYPERTENSION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84881524889     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16.
2. Rosenfeld PJ, Brown DM, Heier JS, et al.; MARINA study group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 419-31.
3. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age related macular degeneration. Retina 2006; 26: 383-90.
4. Coden DJ, Freeman WR, Weinreb RN. Intraocular pressure response after pneumatic retinopexy. Ophthalmic Surg 1988; 19: 667-9.
5. Benz MS, Albini TA, Holz ER, et al. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 2006; 113: 174-8.
6. Hariprasad SM, Shah GK, Blinder KJ. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol 2006; 141: 200-1.
7. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908. Epub 2011 Apr 28.
8. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007; 42: 807-11.
9. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 2007; 27: 1044-7.
10. Johnson D, Gottanka J, Flugel C, Hoffmann F, Futa R, Lutjen-Drecoll E. Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids. Arch Ophthalmol 1997: 115: 375-83.
11. Kubota T, Okabe H, Hisatomi T, Yamakiri K, Sakamoto T, Tawara A. Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide. J Glaucoma 2006; 15: 117-19.
12. Shafranov G, Soltau JB. Glaucoma associated with inflammation; in: Zimmerman TJ, Kooner KS, eds. Clinical Pathways in Glaucoma. New York: Thieme, 2001: 148-50.
13. Lee K, Yang H, Lim H, Lew HM. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection. Retina 2009; 29: 1409-17.
14. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2010; 95: 1111-1114. Epub 2010 Aug 11.
15. Kahook MY, Kimura AE, Wong LJ, Ammar DA, Mayacotte MA, Mandava N. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009; 40: 293-5.
16. Semoun O, Blumen-Ohana E, de Preobrajensky N, Nordmann JP., Acute angle-closure glaucoma complicating an intravitreal injection of bevacizumab. J Fr Ophthalmol 2009; 2: 58+e1-e4.
17. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2012; 21 (4): 241-7.
18. Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 2011; 31 (6): 1028-35.
19. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010; 26 (1): 105-10.